A symposium beginning Monday at 1:30 p.m. PT in Ballroom 20A-C will feature Arun J. Sanyal, MD, and other investigators sharing new data on retatrutide and its effects on obesity, type 2 diabetes, and nonalcoholic steatohepatitis. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Starting soon: Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results
